EN | UA
EN | UA

Help Support

Back

Effect of total stromal cells and platelet-rich plasma on knee osteoarthritis pain

Intra-articular Injection Intra-articular Injection
Intra-articular Injection Intra-articular Injection

The purpose of a single-blind randomized clinical trial was to examine the effects of a single intra-articular injection of autologous total stromal cells (TSC) and platelet-rich plasma (PRP) on osteoarthritis knee pain, general physical function, and articular cartilage thickness.

See All

Key take away

In patients with knee osteoarthritis, a single injection of total stromal cells and platelet-rich plasma lessens pain while enhancing  physical function and cartilage thickness.

Background

The purpose of a single-blind randomized clinical trial was to examine the effects of a single intra-articular injection of autologous total stromal cells (TSC) and platelet-rich plasma (PRP) on osteoarthritis knee pain, general physical function, and articular cartilage thickness.

Method

The American College of Rheumatology criteria was used to diagnose knee osteoarthritis, and patients were then randomized to treatment (TSC and PRP) and control groups. The primary knee osteoarthritis score was determined using the Kallgreen-Lawrance (KL) scoring method. The Western Ontario and McMaster Universities Arthritis Index (WOMAC) for physical function, the medial femoral condylar cartilage (MFC) thickness (millimetres) under ultrasonogram, and the Visual Analogue Scale (VAS, 0–10 cm) for pain were recorded and contrasted between groups prior to and post-treatment.

Data analysis was done. With the aid of the Mann-Whitney U-test, inter-group differences were compared. The Wilcoxon-sign test was used for estimating pre- and post-intervention outcomes. A p-value of <0.05 was regarded as clinically meaningful.

Result

Overall, 15 subjects in the treatment group were given intra-articular TSC and PRP preparation, while 15 individuals in the control group underwent quadriceps-strengthening exercises instead of receiving an injection. VAS for pain, WOMAC physical function, and cartilage thickness prior to and 2 weeks post-intervention did not significantly differ between the groups. After 12 and 24 weeks of therapy, the treatment group's VAS for pain and WOMAC physical function scores remarkably improved.

A profound difference was witnessed in the groups' pain and physical function scores. The mean femoral cartilage thickness did not alter considerably for either the right or left knee until the end of 24 weeks (U=175.00, p=0.009 two-tailed and U=130.00, p=0.016 two-tailed, respectively). While improvement in physical function and pain occurred earlier, alteration in cartilage thickness took more time.

Conclusion

With no noticeable adverse events, an intra-articular autologous adipose-tissue-derived stromal cell improves knee osteoarthritis symptoms, functional ability, and articular cartilage thickness.

Source:

Cureus

Article:

Outcome of Intra-articular Injection of Total Stromal Cells and Platelet-Rich Plasma in Primary Knee Osteoarthritis: A Randomized Clinical Trial

Authors:

Moshiur R. Khasru et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: